Compare MLM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | RVMD |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 30.1B |
| IPO Year | 1996 | 2020 |
| Metric | MLM | RVMD |
|---|---|---|
| Price | $491.17 | $191.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 19 |
| Target Price | ★ $689.36 | $140.84 |
| AVG Volume (30 Days) | 670.1K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 29.27 | N/A |
| Revenue | ★ $6,150,000,000.00 | N/A |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $7.98 | $533.02 |
| P/E Ratio | $16.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $490.48 | $42.18 |
| 52 Week High | $710.97 | $224.31 |
| Indicator | MLM | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 36.28 |
| Support Level | N/A | $177.04 |
| Resistance Level | $636.33 | $194.19 |
| Average True Range (ATR) | 12.16 | 6.91 |
| MACD | -0.80 | -2.61 |
| Stochastic Oscillator | 6.08 | 1.11 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.